Pharmaceutical futures: A fiendish puzzle

Abbott, Alison

doi:10.1038/4551164a

Cited by 3 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most actively developing screening techniques are high--throughput screening (HTS) (computer simulated molecular targeting based on biochemical pathway), new chemical entities (NCE) (a new therapeutic molecule or compound that has not been tested on humans), and (3DMD) (3D molecular docking), specifically 3D modeling of interacting molecules with a known structure, based on their spacial arrangement [7,8]. However, ever though research in this has made a great progress, at present certain crisis is observed in the methodology of search for new drugs, since computer modeling has failed to justify expectations and investments, and this situation forces pharmaceutical companies to search for new approaches to investing into pharmaceutical industry [9].…”

Section: Biosensor Screening At the Stage Of Drug Developmentmentioning

confidence: 99%

Metrological approaches to drug development. Fast screening using universal biosensors at the stage of drug development

et al. 2012

View full text Add to dashboard Cite

We expect that in the near future drug development will become the most interesting and demanded application of the suggested approach. Taking a known drug as the reference point and performing its chemical modification, one can sharply reduce the time and financial expenses for bioactivity testing of new substances and experimentally predict its general toxicity on a biological model the most adequate to human body.Development and commercialization of a new drug is a long-term and expensive process. It takes 10-20 for a biologically active substance to pass way from laboratory synthesis or isolation to application as a drug [1]. If 20 years ago this process costed slightly more than $300 mln, then now the cost may reach $1 bln. Therewith, only 3 of 5 newly commercialized drugs make a profit greater or equal to expenses on its development.One of the approaches to the problem of reduction of terms and costs of drug development involves screening of biologically active substances and drugs on their basis at the development stage. Such screening can be performed by means of biosensors.The end of XX century was marked by the advent of a new field of science-biosensing. Unfortunately, already in a few years the term "biosensors" started to be related to electronic devices, and attention started to be focused exclusively on the development of high-selectivity specific biosensors. However, with time, researchers returned to nonspecific universal bio-sensors on the basis of live systems. Biosensing as one of the components of the methodology of drug development allows fast selection of physiologically active substances as potential candidates for medical applications.

show abstract

Section: Biosensor Screening At the Stage Of Drug Developmentmentioning

confidence: 99%

Metrological approaches to drug development. Fast screening using universal biosensors at the stage of drug development

et al. 2012

View full text Add to dashboard Cite

show abstract

Unveiling the role of network and systems biology in drug discovery

Pujol

Mosca

Farrés

et al. 2010

Trends in Pharmacological Sciences

315

198

View full text Add to dashboard Cite

Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases

2009

View full text Add to dashboard Cite

Background: The production of peroxide and superoxide is an inevitable consequence of aerobic metabolism, and while these particular 'reactive oxygen species' (ROSs) can exhibit a number of biological effects, they are not of themselves excessively reactive and thus they are not especially damaging at physiological concentrations. However, their reactions with poorly liganded iron species can lead to the catalytic production of the very reactive and dangerous hydroxyl radical, which is exceptionally damaging, and a major cause of chronic inflammation.

show abstract

Pharmaceutical futures: A fiendish puzzle

Cited by 3 publications

References 3 publications

Metrological approaches to drug development. Fast screening using universal biosensors at the stage of drug development

Metrological approaches to drug development. Fast screening using universal biosensors at the stage of drug development

Unveiling the role of network and systems biology in drug discovery

Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases

Contact Info

Product

Resources

About